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 Abstract  
 
Purpose of review 
Rheumatoid arthritis (RA) is a systemic, autoimmune disease resulting in the 
destruction of affected joints. Even though current therapies with biologics such as 
TNF- blockers yield significant improvement for the patients, the disease is not 
curable yet. Therefore, we need novel strategies for better therapies. 
 
Recent finding 
The growing knowledge of epigenetics might give us new insights into the 
pathogenesis of autoimmune diseases. In the last year several new findings about 
epigenetic modifications of gene expression were reported in different arthritides. 
These modifications describe changes in the expression of DNA that result from 
methylation, posttranslational modifications of the histone proteins including 
acetylation/deacetylation, sumoylation, methylation and microRNAs. Most 
interestingly, these modifications seem to act in concert and are associated with the 
cirardian metabolic rhythm of cells. 
  
Summary 
This review summarizes reports from the last year about epigenetic modifications of 
gene expression via acetylation/deacetylation, including sirtuins, sumoylation, 
methylation and/or microRNAs in RA and other arthritides, providing potential 
strategies for better therapies and encourages the development of specific epigenetic 
drugs.  
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 Introduction: 
We summarize here reports from the last year about epigenetic modifications that 
control the regulation of gene expression in autoimmune diseases. Epigenetic 
modifications of synovial cells such as fibroblasts, chondroyctes and endothelial cells 
and also from PBMCs were reported in different arthritides. This knowledge gives us 
novel insights into the pathogenesis of these diseases and allows in future the 
development of more specific epigenetic drugs.  
 
 
Text of review: 
HDACs and sirtuins 
Protein acetylation is the best described posttranslational modification of histones 
that is able to regulate the transcription of genes. Acetylation of histones is mediated 
by a group of enzymes so called histone-acetyltransferases (HATs) that transfer 
acetyl groups from acetyl-coenzyme A to the -amino group of lysines. HATs are 
counterbalanced by the activity of histone-deacetylases (HDACs). HDACs are 
divided into three classes based on their homologies with the yeast transcriptional 
repressors: Rpd3p (reduced potassium dependency gene 3) belonging to class I 
(HDAC1, 2, 3, 8 and 11); Hda1p (a subunit of histone deacetylase A complex) 
belonging to class II (HDAC4, 5, 6, 7, 9, and 10); and Sir2p (silent information 
regulator 2) belonging to class III (Sirtuins 1 to 7) (1, 2). In 2009, a report about the 
altered distribution pattern of HDACs on chromatin, the dissociation of the 
deacetylase activity from the DNA binding sites and the function of gene repression 
provided novel insights into the function of chromatin remodeling enzymes. In 
addition, HDACs themselves are also subject to post-translational modifications that 
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influence stability, localization, activity and non-histone protein-protein interactions on 
the DNA binding sites (3). Several novel targets of HDACs isoforms such as 
transcription factors are described recently. This knowledge may provide us better 
therapeutically strategies in RA (4, 5) and other arthritides by targeting the catalytic 
activity of HDACs, their DNA binding regions and/or their post translational 
modifications (6).  
To control the acetylation status in the cells HATs and HDACs work antagonistically. 
The removal of the positive charge from the histone protein during acetylation is 
commonly associated with active gene transcription whereas deacetylation is 
associated with gene repression, indicating that acetylation and deacetylation are 
highly dynamic processes. Recently, Wang et al reported a novel distribution pattern 
for these enzymes by mapping the genome-wide distribution of HATs and HDACs in 
human primary resting CD4+ T cells. They showed that both- HATs and HDACs are 
primarily targeted to transcribed regions of active genes (7). They show two major 
functions for the accumulation of HDACs on active gene regions. First, the HDACs 
work to reset chromatin by removing the acetylation marks. And secondly, HDACs 
have a function in H3K4 primed genes, where transient binding of HATs and HDACs 
prevents RNA polymerase II (Pol II) from binding and keeps the promoter of a gene 
in an inactive state. Totally silent genes which are associated with H3K27 methylation 
signals did not show detectable levels of acetylation and deacetylation activities. 
These results help us to understand how chromatin remodeling enzymes work in the 
transcriptional regulation. However, the specific repression of genes by HDAC 
isoforms, their binding sites on DNA and interactions with other DNA binding 
molecules is not known yet. 
HDACs have been reported to be included in many cellular pathways and their 
dysreguation has been linked to multiple cancers as well as to autoimmune diseases 
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(8-12). Our group reported a reduction of total HDAC activity in the synovial tissue of 
patients with RA and a significant downregulation of the isoform proteins HDAC1 and 
HDAC2 suggesting that HDACs are intrinsically reduced and therefore might not be 
suitable for further treatment by HDAC inhibitors (HDACi) (13). However, in several 
animal studies HDACi showed beneficial effects for treatment of arthritis (14-16). 
These results show that further knowledge of HDACi on histones and non-histone 
proteins in different cell populations is necessary before these drugs can be safely 
used for the treatment of RA (Table 1).  
To understand the function of acetylases/deacetylases in regard to the production of 
matrix metalloproteinases (MMPs) we established their expression pattern in the 
synovial fibroblasts (RASF) which are the effector cells leading to cartilage 
destruction in RA (17). In contrast to synovial tissues, we could not detect a 
decreased expression of HDAC1 and 2 in TNF- and IL-1β stimulated RA synovial 
fibroblasts, and therefore these HDACs do not contribute to the increased activity of 
acetylation seen in the tissue. But, stimulation of the RASF with TNF- and IL-1β to 
mimic the inflammatory milieu in the affects joints resulted in an increase of the global 
acetylation status of the cells and reduced expression of the isoforms HDAC 3, 4 and 
7 (18). Treatment of the cells with the HDACi trichostatin A resulted in a significant 
downregulation of HDAC7 (19). In addition, TSA also downregulated the expression 
of MMPs in stimulated cells, while their expression in unstimulated cells was 
unaffected, suggesting an interaction of HDACs with molecules from the 
inflammatory pathway (20). Silencing of HDAC7 by siRNA resulted in reduced 
expression of MMP-1 and 3 implying that specific targeting of HDAC7 could be a 
strategy for anti-destructive therapy. In contrast, Horiuchi H et al reported a 
significant overexpression of HDAC1 in RASF compared to OASF at the mRNA and 
protein level. HDAC2 transcripts showed the highest mRNA expression levels of all 
 6
HDACs in RA and OASF. Knock down of HDAC1 and HDAC2 by siRNA in RASF 
resulted in significantly reduced cell viability even in the presence of a strong growth 
factor such as plateled-derived growth factor (PDGF), upregulated expression of the 
cell cycle proteins p16 and p21 and p53, and increased TUNEL positive cells. 
Knockdown of HDAC1 in addition upregulated TNF- induced MMP-1 production by 
RASF.  Therefore, these HDAC isoforms induce  proliferation, reduce apoptosis and 
play a role in inhibiting MMPs (21). Since acetylation and deacetylation are highly 
dynamic processes influenced by the stage of development, different expression 
patterns of HDACs might result from the use of different passages of cultured 
synovial fibroblasts from patients with RA and OA. Our group only used cells from 
passages 4 to 6 to make sure that the isolated cells were a pure culture of fibroblasts. 
Horiuchi M et al used RASF as early as from passage 2 to 5 and OASF from 
passage 1 to 2 for their experiments. 
A misregulation of HDAC isoforms was also reported in other arthritides. 
Overexpression of HDAC1 and 2 proteins was demonstrated in human chondrocytes 
from OA cartilage consistent with a downregulation of cartilage marker genes. 
Overexpression of these HDACs repressed specific cartilage marker genes such as 
aggrecan and collagen 2 and to a different extent also collagen 9, collagen 11, 
dermatopontin and cartilage oligomeric protein (COMP) whereas silencing of HDAC1 
and 2 by siRNA or HDACi increased cartilage gene expression. Removal or 
exchange of one of the DNA binding sites, the carboxy-terminal domain (CTDs), 
showed altered target gene repression specificity for HDAC1 and HDAC2. The most 
interesting point of this study is that these CTDs can function independently of the 
HDAC enzymatic activity to target HDACs to specific genes (22). Others reported 
elevated levels of the isoform, HDAC7 in OA cartilage compared to healthy donors. 
Silencing of HDAC7 in a human chondrosarcome cell line suppressed the IL-1 
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induced expression of MMP13 suggesting that specific HDAC7 suppression may 
prevent the increased matrix degradation in OA (23). 
In another study, HDAC inhibitors were shown to antagonize FGF2 and IL-1 induced 
expression of MMP1, 3 and 13 in cultured human articular chondrocytes, also 
suggesting HDAC inhibition as intervention in OA. But further analysis showed that 
also cartilage matrix proteins such as COL2A1 and aggrecan were also reduced by 
the treatment with TSA. Whether HDACi may slow down cartilage turnover and 
thereby inhibit the progression of cartilage destruction to preserve existing cartilage 
needs to be evaluated in animal models (24).  
Together, the mentioned studies suggest that HDACs might have several functions 
and targets, namely the deacetylase activity on histone proteins and non-histone 
proteins and repression of gene expression by binding to promoter regions alone or 
in complex with other DNA binding molecules. Therefore, it is very important to 
explore all the possible effects of HDAC isoforms before using them for treatment. 
Based on the evidence that epigenetic modifications of gene regulation contribute 
also to the angiogenic function of endothelial cells Urbich et al analyzed the function 
of histone deacetylase isoforms in angiogenesis. This study is of interest because 
angiogenesis plays an important role in RA where inflammation and subsequent joint 
destruction in the synovium are also dependent on the development of new 
vasculature. They showed that HDAC5 is a negative regulator of angiogenesis in 
endothelial cells by binding to the promoter and repressing FGF2 and Slit2. Knock 
down of HDAC5 lead to an increased endothelial cell migration, sprouting, and tube 
formation whereas overexpression of HDAC5 decreased sprout formation. In 
contrast, silencing of other histone deacetylases such as HDAC7 and HDAC9 
blocked angiogenesis (25). The function of HDAC7 in endothelial cells has been 
attributed to the repression of the transcription factor MEF2 resulting in the inhibition 
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of MMP-10 (26) whereas the proangiogenic function of HDAC9 was not described 
before. Of interest is that the repressive function of HDAC5 was independent of the 
direct deacetylase activity of HDAC5 suggesting an interaction with other DNA 
binding molecules or other HDAC isoforms as it is described for class II HDACs. 
However, the deacetylase- deficient HDAC5 mutant which lacks also the C-terminus 
still repressed endothelial function, implying other mechanism for the antiangiogenic 
effects. The authors suggest that the N-terminal part of HDAC5 might also repress 
transcriptional activity through interaction with co-repressors such as HP1 or CtBP.  
In RA HDAC inhibitors were also used to alter gene expression in hematopoietic 
cells. In RA, regulatory T cell function is defective because they are unable to prevent 
the release of inflammatory cytokines from effector CD4+ CD25- T cells, they do not 
suppress effector T cell proliferation, and they show low levels of FOXP3 expression. 
Saouaf et al showed that treatment with the HDACi valproic acid (VPA, i.p., 400 
mg/kg) increased regulatory T cell function and decreased the incidence and severity 
of collagen-induced arthritis. They could observe that VPA increased the suppressive 
function of CD4+CD25+ Tregs and the number of CD25+FOXP3+ Tregs in vivo (27, 
28). 
Of interest for the pathogenesis in RA (29, 30) was also the report from Villagra et al 
showing that histone deacetylases regulate the expression of genes involved in 
inflammatory responses. They showed that HDAC11 interacts with the transcription 
activators STAT3 or Sp1 on the promoter of the gene encoding interleukin 10 and 
negatively regulated the expression of this cytokine in mouse and human antigen-
presenting cells (APCs) (31). Overexpression of HDAC11 in APCs activated naïve 
antigen-specific CD4+ T cells whereas downgregulation of HDAC11 impaired antigen-
specific CD4+ T cell response. In this case, gene repression of HDAC11 seems to be 
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mediated by the enzymatic activity, as overexpression of an HDAC11 mutant with a 
deleted deacetyltransferase domain did not inhibit IL-10 expression.  
Posttranslational modifications of proteins, such as citrullination, which is produced 
by the calcium binding peptidylarginine deiminases (PADIs) are of particular interest 
in the pathogenesis of RA (32, 33). Two isoforms, PADI2 and PADI4, are 
overexpressed in RA and contribute to the generation of specific substrates for the 
anti-citrullinated protein antibodies (ACPA). In addition, PADI4 itself is a target of 
autoantibodies in RA. PAD4 plays a physiological role in regulation of gene 
expression via citrullination of arginine residues of histone proteins (H3R2, 8, 17 and 
26, and H4R3 and 42), thereby antagonizing histone methylation. Denis et al 
reported recently a functional connection between deimination and deacetylation of 
histones (34). They could show that PADI4 associated with HDAC1 both in vitro and 
in vivo to repress gene transcription of the estrogen-regulated pS2 promotor.  
Sirtuins, the class III HDACs, differ from the zinc dependent class I and class II 
HDACs because they require nicotinamide adenine dinucleotide (NAD+) as an 
essential cofactor. In addition, sirtuins also deacetylate non-histone proteins in the 
nucleus (SIRT1, 6, 7), in the cytoplasm (SIRT2) or in mitochondria (SIRT3, 4, 5). All 7 
members of this family of which SIRT1 has become the most well studied protein are 
associated with the regulation of metabolism, cellular survival and aging (35, 36). Of 
interest, SIRT1-null mice suffer from a mild autoimmune condition that is apparent by 
the deposition of immune complexes in the liver and kidney and they develop high 
titer anti-nuclear antibodies. Older animals develop a sporadic a form of diabetes 
(37).  
For RA, sirtuins might play an important role since they are also considered as 
mediators of inflammation. They consume NAD+ as an essential cofactor and 
generate nicotinamide as they hydrolytically remove an acetyl group from a lysine 
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residue from the target protein. The deacetylation process includes the hydrolysis of 
NAD+, yielding nicotinamide and an O-alkylamidate intermediate O-acetyl-ADP-
ribose (OAADPr). The cofactor NAD+ directly activates sirtuins while nicotinamide as 
well as NAD in its reduced form NADH directly inhibit sirtuin enzyme activity. Beyond 
its central role in oxidative metabolism, NAD is increasingly considered to be involved 
in the regulation of intracellular signaling (38).  
In vivo, sirtuins are tightly regulated by modulators of sirtuin activity. SIRT1 interacts 
and can be activated by active regulator of SIRT1 (AROS). AROS works as a 
derepressor by displacing the inhibitory factor deleted in breast cancer1 (DBC1). 
DBC1 was shown to bind and inhibit SIRT-1-catalyzed deacetylation of p53 in vivo by 
binding of NAD+ and OAADPr to the DBC1 complex. Resveratrol, a phytoalexin 
produced naturally by several plants, activates SIRT1 by displacing the inhibitory 
factor DBC1. The disruption of SIRT1- DBC1 binding offers novel therapeutic 
strategies to activate SIRT1 expression in vivo by pharmaceutical compounds (36). 
Recent reports show that that DBC1 was upregulated in cartilage of patients with OA 
suggesting SIRT1 as a regulator for gene expression in chondrocytes. Furthermore, 
they reported that the decreased levels and activity of SIRT1 in OA articular cartilage 
are associated with an increased level of matrix degrading enzymes such as MMP-3 
and -13 as well as with increased apoptosis through the repression of tyrosine 
phosphatase 1B (PTP1B) (39).  
Other reports show an association between the circadian clock and the cellular 
metabolism which is also of interest for RA (40). The transcriptional regulators 
CLOCK and BMAL1 dimerize and bind to E box enhancer sequences in the genes 
for period (per) and cryptochrome (cry). The expression of CRY and PER proteins 
subsequently leads to the repression of CLOCK: BMAL1 transcripts suggesting a 
translational-transcriptional feedback mechanism (41). Of interest, TNF- inhibits 
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CLOCK-BMAL1-induced activation of gene promotors suggesting that the 
proinflammatory milieu in autoimmune diseases impairs clock gene functions and 
causes fatigue in RA patients (42). Hashiramoto et al showed a disturbed circadian 
rhythmic expression of PER in the nuclei of inflammatory synovial cells, disturbed 
expression of BMAL1 in spleen cells after induction of experimental arthritis in mice.  
(43). Deletion of Cry in this model resulted in an increased number of activated T 
cells and induced the expression of TNF-  in the spleen. Induced arthritis in Cry1-
/Cry2- knockout animals showed worsening of joint swelling, and upregulation of 
TNF- , IL-1β and IL-6, MMP-3, Wee-1 and c-Fos whereas ectopoic expression of 
Cry1 significantly reduced the activation of TNF-a gene suggesting biological clock 
and arthritis influence each other. 
Most interestingly, the circadian regulator CLOCK is a histone acetyltransferase 
which is counterbalanced by the deacetylase activity of SIRT1. In vivo CLOCK 
acetylates and activates its partner BMAL1. Both together induce the circadian 
expression of nicotinamide phosphoribosyltransferase (NAMPT) by binding to its E-
boxes in the promoter. Nampt on the other site provides the important cofactor NAD+ 
for the counter player SIRT1. For the deacetylation activity, SIRT1 is also recruited to 
the NAMPT promoter and contributes to its repression and therefore to the the 
circadian synthesis of its own coenzyme. The NAMPT inhibitor FK866 significantly 
lowered cellular NAD+ and NAM levels and increased acetylation of the CLOCK 
partner BMAL1 similar to the effect of inhibition of SIRT1 (44, 45). 
Nampt, also known as PBEF (Pre-B-cell colony-enhancing factor) or visfatin, is 
upregulated in the synovial tissues from patients with RA and induced by toll-like 
receptors signaling in isolated synovial fibroblasts (RASF) (46).  
Since calorie restriction decreases NADH levels, changes in the intracellular 
NAD+/NADH ratios have also impact on sirtuin deacetylase activity in the cells. In 
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addition, metabolic stress such as prolonged fasting is known to activate Nampt 
which regulates SIRT1-dependent activities by its capacity to provide the SIRT-
cofactor NAD (38, 47). Our group reported Nampt/PBEF not only as a novel marker 
of inflammation in RA with proinflammatory but also matrix–degrading activities (46). 
Furthermore, we could show that RNA interference-mediated gene therapy of PBEF 
reduces the severity of collagen-induced arthritis in mice suggesting PBEF as a 
crucial proinflammatory and destructive mediator of joint inflammation in vivo (48). 
Whereas in smooth muscle cells PBEF delays cellular senescence through SIRT1-
mediated deacetylation and inactivation of p53 (47, 49) the mechanism of PBEF 
regulation of sirtuins in RA is currently under investigation. Recently, our group 
reported the expression of all sirtuins in isolated synovial fibroblasts from patients 
with RA (RASF) with a significant upregulation of SIRT 1 and 4 compared with cells 
from osteoarthritis (OA). The expression level of single sirtuin-isoforms could be 
downregulated by different ligands of the Toll-like receptor (TLR) pathway whereas 
PBEF was up-regulated suggesting a regulatory role for sirtuins in the innate immune 
system via TLR signaling (50). 
Another important target for SIRT1 in RA is nuclear factor-kappa B (NFB), the 
master regulator of innate immune responses, regulating inflammation, cell cycle and 
apoptosis. SIRT1 downregulates NFB mediated proinflammatory effects by 
deacetylating its subunit RelA/p65 (51, 52). In addition, activation of SIRT-1 resulted 
in inhibition of TNF- and other proinflammatory molecules such as ICAM, MCP-1, 
RANTES and TGF-β suggesting that SIRT1 acts through multiple downstream 
pathways (35, 53). 
Sumoylation is one of the modulators of sirtuin activity. SIRT1 can be modified at 
Lys-734 by the addition of a SUMO-group which increases the SIRT1 deacetylation 
activity (54). In contrast, the recruitment of the SUMOylase SENP-1 resulted in 
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desumoylation and therefore repression of SIRT1 deacetylase activity and 
consequently acetylation and activation of target proteins such as p53. We reported 
an intrinsic upregulation of SUMO in synovial fibroblasts from patients with RA 
leading to their increased resistance of apoptosis by SUMOylation of promyelocytic 
leukemia protein (PML) and recruitment of DAXX to PML nuclear bodies (NBs) (55, 
56). In contrast, the induced upregulation of the SUMO-protease SENP-1 which is 
normally downregulated in RASF was able to reverse this effect. Since SIRT-1 is also 
recruited to the PML NBs in the cells, and binds and regulate p53 expression an 
increased SUMOylation of SIRT1 might contribute to the apoptosis resistance of 
RASF (57).  
SIRT1 is known to regulate cell survival and apoptosis of several cells. Recently, it 
was shown that SIRT1 also regulates apoptosis in human chondrocytes which is a 
characteristic feature of OA. A reduced level of SIRT1 was found in chondrocytes 
from patients with OA compared to normal. Induced catabolic, mechanical and 
nutritional stress inhibited the expression of SIRT1 in these cells. Inhibition of SIRT1 
by sirtinol and nicotinamide or siRNA increased whereas the activation of SIRT1 by 
resveratrol decreased the percentage of apoptotic cells. At the same time 
mitochondria-related signals such as Bax and Bcl-2 were increased and decreased 
respectively suggesting that SIRT-1 regulates apoptosis through modulation of 
mitochondria related signaling pathways and could be a novel target for upregulation 
in the therapy in OA (58).   
Even though SIRT1 as a deacetylase is expected to negatively effect transcription 
Dvir-Ginzberg et al demonstrated that the up- or downregulation of SIRT1 in human 
chondrocytes by resveratrol or siRNA function as a positive/negative regulator of 
cartilage specific molecules such as collagen 2, collagen 9 and aggrecan. SIRT1 
thereby deacetylates the cartilage specific transcription factor Sox9 and enhances 
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transcription of collagen 2 in association with co-activators such as the transcription 
factor Sp1. Since NAD+ is provided by NAMPT as a SIRT1-cofactor, NAMPT 
indirectly affects cartilage-specific gene expression. This suggests an imbalance of 
SIRT1 and NAMPT in OA (59). 
In RA angiogenesis plays an important role because inflammation and subsequent 
joint destruction in the synovium is also dependent on the development of new 
vasculature. We defined recently hypoxic areas, particularly at sites of synovial 
invasion into bone in arthritic joints, by EF5 staining. Hypoxia induced the 
overexpression of DNA binding/differentiation 2 (ID-2) in synovial fibroblasts, which 
leads to an increased differentiation of osteoclasts from bone marrow precursors, 
suggesting that hypoxia-induced ID-2 may contribute to joint destruction in RA 
patients by promoting synovial fibroblast-dependent osteoclastogenesis (60, 61). 
Hypoxia inducible factor (HIF)-1alpha and HIF-2alpha are transcriptional regulators 
that control the genes induced during hypoxia. Both are significantly overexpressed 
in the synovial lining and stromal cells in RA relative to normal as shown by 
immunohistochemistry (62). Recently, Dioum et al showed that during hypoxia HIF-
2a is bound and thereby deacetylated and activated by SIRT1. The SIRT1 inhibitors 
NAM or sirtinol reduced, and the SIRT1 activator resveratrol increased the ability of 
SIRT1 to augment transcription of HIF-2 target genes superoxide dismutase 2 
(Sod2), vascular endothelial growth factor A (VEGF-A) and erythropoietin (Epo). 
Whether SIRT1 itself is activated by hypoxia is not clear yet. But the SIRT1/HIF2a 
complex formation as well as SIRT1 mediated deacetylation of acetylated HIF2a 
during hypoxia or other environmental stress offers novel therapeutic opportunities 
also for RA (63, 64). 
The function of SIRT1 in the endothelium was revealed by an impaired ability of SIRT 
1 mutant mice to form new vessels in response to angiogenic signals (65, 66). 
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Although endothelial cells express all sirtuins (1 to 7), knock down of SIRT1 was 
associated with a loss of sprouting angiogenesis in vitro. Since RA is characterized 
by inflammation and endothelial dysfunction (67)  these results suggest that SIRT1 is 
a novel modulator of normal endothelial function and that overexpression of SIRT1 
might be vasoprotective (68).  
However, we have only limited knowledge about the mechanisms that regulates the 
function of SIRT1. Recently, miRNA 217 was observed to be overexpressed during 
endothelial senescence whereas SIRT1 levels decreased at the same time. 
Modulation of miRNA 217 alters the senescence process in endothelial cells and 
affects the acetylation state of the SIRT1 targets FOXO1 and eNOS which are 
important factors for angiogenesis and tube formation. Therefore, microRNA217 
might act as an endogenous inhibitor of SIRT1 (69).  
 
Sumoylation 
Posttranslational modification of DNA binding molecules like transcription factors by 
the small ubiquitin-releted modifier SUMO has been correlated with transcriptional 
repression. Several proteins are recruited to promotors in a SUMO-dependent 
manner, such as HDAC2, the histone demethylase LSD1, the histone 
methyltransferase SETDB1, and the chromatin associated proteins HP1 suggesting 
SUMO as a central player in coordinating chromatin modifications that regulate gene 
expression (70). Our group showed that the SUMOylation pathway regulates the 
production of matrix degrading enzymes by the activity of HDAC4.  We showed an 
increase of acetylated histone 4 in the promoter of MMP-1 in RASF compared to 
OASF which was decreased by the overexpression of the SUMO-specific protease 
SENP-1. Furthermore, overexpression of SENP-1 in RASF significantly reduced the 
production of MMP-1 and therefore the invasiveness of RASF due to an 
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accumulation of HDAC4 on the MMP-1 promotor. Interference with these epigenetic 
control mechanisms might be of value for anti-destructive treatment in RA (71).  
 
 
Methylation 
Methylation is the best analyzed posttranslational modification regulating gene 
expression and contributing to several diseases, in particular autoimmune diseases 
(72, 73). Recently, we demonstrated that the DNA in RA synovial fibroblasts is 
hypomethylated, resulting in the activated and aggressive phenotype of these cells 
(74). Our group showed also that proliferating RASFs are deficient in DNA 
methyltransferase 1 (DNMT1) compared to OASF and the DNA showed fewer 5-
methylcytosine and methylated CG marks upstream of an L1 open-reading frame. 
Moreover, using 5-azacytydine, a potent inhibitor for DNMT1, on healthy fibroblasts 
the activated phenotype could be induced by upregulation of genes, including growth 
factors and receptors, extracellular matrix proteins, adhesion molecules, and matrix-
degrading enzymes. These data suggest that DNA hypomethylation contributes to 
the chronicity of RA and could be responsible for the limitation of current therapies 
(75). 
Furthermore, downregulation of DNMTs seems not only to affect fibroblasts but also 
has consequences for hematopoietic cells. Liu et al reported that decreased DNMT 
levels contribute to abnormal gene expression in senescent CD4+CD28- T cells (76). 
This is of interest for RA since chronic stimulation of CD4+ T cells in vitro results in 
the development of a senescent CD28- subpopulation. 
Novel therapeutic intervention using microRNAs might be also of value for RA since 
the expression of DNMTs themselves are regulated by specific microRNAs as 
recently reported (77). Garzon et al identified binding sites for miR-29b within the 
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3`UTR of DNMT 3A and 3B, whereas DNMT1 is indirectly regulated by miR-29b 
which targets Sp1, a transactivator of the DNMT1 gene (78). The enforced 
expression of miR-29b in leukemia cells resulted in a marked reduction of the 
expression of DNMT1, 3A, and 3B, suggesting a novel functional link between 
miRNAs and aberrant DNA hypermethylation.  
 
MicroRNA 
MicroRNAs are small RNA molecules that can negatively control their target gene 
expression posttranscriptionally. They play a key role in all physiological processes 
by direct targeting or modulating chromatin structure. Recent reports show that 
microRNAs can regulate epigenetic modifications but can also be a target of 
epigenetic modifications (79). In 2009 several studies reported about altered 
expression patterns of microRNAs in synovial cells from patients with RA (80-85).  
Our group reported first an increased expression of microRNA-155 and -146 in RA 
and their involvement in the modulation of the agressive phenotype of RASF (80). In 
addition, we could demonstrate that miRNA-203 is overexpressed and involved in the 
regulation of IL-6 and MMP-1 in RASF, which contributes to their activated 
phenotype. Most interestingly, we could show a stimulatory effect of the 
hypomethylating drug 5-azacytidine on the expression of miRNA-203 in healthy 
fibroblasts suggesting that epigenetic mechanisms interact with altered microRNA 
levels in these cells (82). 
Further, downregulated levels of miR-124a were reported in synovial fibroblasts from 
patients with RA (83). Nakamachi et al showed that transfection of precursor miRNA-
124a inhibits the proliferation of RASF via binding to cyclin-dependent kinase 2 
(CDK-2) and monocyte chemoattractant protein 1 (MCP-1) mRNA. Overexpression of 
miRNA- 124a in RASF suppressed the production of CDK-2 and MCP-1 protein 
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whereas overexpression of other miRNAs such as pre-miR-146a, pre-miR-223 in 
OASF did not induce any cytokine or chemokine expression in these cells. 
Alsaleh et al showed that RASF treated with LPS express mRNA but no protein for 
IL-18 due to an increased degradation of the transcripts. At the same time they 
observed an upregulation of microRNA-346 in these cells. Suppression of this 
microRNA resulted in the expression of IL-18 protein by indirect regulation of the 
LPS-induced Bruton`s tyrosine kinase, which is typically involved in the stabilization 
of cytokine mRNAs (84). These results show first that cytokine secretion can be 
negatively regulated at the posttranscriptional level by microRNAs and secondly, that 
microRNAs can be induced by ligands of the innate immune system and can act as 
potential negative regulators of inflammation.  
Most interestingly, Nagata et al have proven for the first time beneficial effects of in 
vivo administered microRNAs. They demonstrated the induction of apoptosis via 
downregulation of Bcl-2 in the synovium of mice with autoantibody-mediated arthritis 
by the intraacticular injection of double stranded microRNA-15a (85). These results 
might be used for novel therapeutical strategies inducing the overexpression of 
microRNAs in vivo by intraarticular injection of double stranded miRNA into the joints. 
 
 
Conclusion: 
In summary, the reported data clearly demonstrate that the epigenetic modulations 
observed in health and disease are regulated by novel mechanisms including 
acetylation, methylation, sumoylation and microRNA. In this regard a complete new 
class of drugs is evolving (6). 
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